Results 1 - 20 of 2,379 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Show only
| Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
|---|---|---|---|
| 1 |
Material Type: Article
|
|
Secondary Surgical Cytoreduction for Recurrent Ovarian CancerThe New England journal of medicine, 2019-11, Vol.381 (20), p.1929-1939 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1902626 ;PMID: 31722153Full text available |
| 2 |
Material Type: Article
|
|
Therapeutic Potential of Bioactive Components from Scutellaria baicalensis Georgi in Inflammatory Bowel Disease and Colorectal Cancer: A ReviewInternational journal of molecular sciences, 2023-01, Vol.24 (3), p.1954 [Peer Reviewed Journal]2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 1422-0067 ;ISSN: 1661-6596 ;EISSN: 1422-0067 ;DOI: 10.3390/ijms24031954 ;PMID: 36768278Full text available |
| 3 |
Material Type: Article
|
|
Ferroptosis in epithelial ovarian cancer: a burgeoning target with extraordinary therapeutic potentialCell death discovery, 2023-12, Vol.9 (1), p.434-434, Article 434 [Peer Reviewed Journal]The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 2058-7716 ;EISSN: 2058-7716 ;DOI: 10.1038/s41420-023-01721-6 ;PMID: 38040696Full text available |
| 4 |
Material Type: Article
|
|
Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian CancerTargeted oncology, 2019-08, Vol.14 (4), p.465-477 [Peer Reviewed Journal]The Author(s) 2019. corrected publication 2019 ;Targeted Oncology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019, corrected publication 2019 ;ISSN: 1776-2596 ;EISSN: 1776-260X ;DOI: 10.1007/s11523-019-00650-8 ;PMID: 31332693Full text available |
| 5 |
Material Type: Article
|
|
Efficient development and usability testing of decision support interventions for older women with breast cancerPatient preference and adherence, 2019-01, Vol.13, p.131-143 [Peer Reviewed Journal]COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2019 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 Lifford et al. This work is published and licensed by Dove Medical Press Limited 2019 ;ISSN: 1177-889X ;EISSN: 1177-889X ;DOI: 10.2147/PPA.S178347 ;PMID: 30679905Full text available |
| 6 |
Material Type: Article
|
|
The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast CancersJournal of immunology research, 2017-01, Vol.2017, p.1049023-21 [Peer Reviewed Journal]Copyright © 2017 Viriya Kaewkangsadan et al. ;Copyright © 2017 Viriya Kaewkangsadan et al.; This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ;Copyright © 2017 Viriya Kaewkangsadan et al. 2017 ;ISSN: 2314-8861 ;EISSN: 2314-7156 ;DOI: 10.1155/2017/1049023 ;PMID: 28913366Full text available |
| 7 |
Material Type: Article
|
|
The Australian Ovarian Cancer StudyHereditary cancer in clinical practice, 2012-04, Vol.10 (S2), p.A94-A94, Article A94 [Peer Reviewed Journal]2012 Traficante et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ;Copyright ©2012 Traficante et al; licensee BioMed Central Ltd. 2012 Traficante et al; licensee BioMed Central Ltd. ;ISSN: 1897-4287 ;ISSN: 1731-2302 ;EISSN: 1897-4287 ;DOI: 10.1186/1897-4287-10-S2-A94Full text available |
| 8 |
Material Type: Article
|
|
A Backbone for Cancer TherapyAsian Journal of Pharmaceutical Research, 2013-03, Vol.3 (1)Copyright 2018 A & V Publication, distributed by Contify.com ;ISSN: 2231-5683 ;EISSN: 2231-5691Full text available |
| 9 |
Material Type: Thesises (postgraduate)
|
|
Synthesis and Evaluation of Tri-Cyclic Alkaloid-Like Compounds as Anticancer AgentsDatabase copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works. ;ISBN: 9798382084091Digital Resources/Online E-Resources |
| 10 |
Material Type: Newsletter Article
|
|
RESEARCHERS AT OU HEALTH STEPHENSON CANCER CENTER AT THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES EARN GRANT FOR ENDOMETRIAL CANCER RESEARCHUS Fed News Service, Including US State News, 2023Copyright HT Digital Streams Limited Dec 15, 2023Digital Resources/Online E-Resources |
| 11 |
Material Type: Newsletter Article
|
|
Press Release: Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerDow Jones Institutional News, 2023Copyright Dow Jones & Company Inc. Dec 13, 2023Digital Resources/Online E-Resources |
| 12 |
Material Type: Newsletter Article
|
|
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerBusiness Wire, 2023Copyright Business Wire 2023Digital Resources/Online E-Resources |
| 13 |
Material Type: Newsletter Article
|
|
Neoplasm Treatment Market revenue to reach USD 400 Billion by 2035, says Research NesterFinancial Services Monitor Worldwide, 20232022 Global Data Point. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).Digital Resources/Online E-Resources |
| 14 |
Material Type: Newsletter Article
|
|
Celsion Corp Says Poster On Co's Phase I/II OVATION 2 Study To Be Presented At Society Of Gynecology Oncology Virtual Annual Meeting On Women's CancerBenzinga Newswires, 20212020 Benzinga.com - Benzinga does not provide investment advice. All rights reserved.Digital Resources/Online E-Resources |
| 15 |
Material Type: Newsletter Article
|
|
WEEKLY RECAP: MDLINX, INC. NEWS THIS PAST WEEK JAN 08, 2023News Bites - Private Companies, 2023Copyright News Bites Pty Ltd Jan 9, 2023Digital Resources/Online E-Resources |
| 16 |
Material Type: Newsletter Article
|
|
Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician's Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast Cancer: Pivotal Phase III TULIP® Study Showed SYD985 Provided 2.1 Month Increase in Progression-Free Survival Compared to Standard TreatmentPR Newswire, 2021Copyright PR Newswire Association LLC Sep 19, 2021Digital Resources/Online E-Resources |
| 17 |
Material Type: Newsletter Article
|
|
Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician's Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast CancerPR Newswire Europe Including UK Disclose, 2021Copyright © 2021 PR Newswire Europe Limited. All Rights Reserved.Digital Resources/Online E-Resources |
| 18 |
Material Type: Newsletter Article
|
|
Oncology Drugs Market Worth $848.94 Billion by 2030 at 9.51 % CAGR: The revenue of the Oncology Drugs Market was USD 177.54 Billion in 2021 and is projected to reach USD 474.06 Billion in 2030 with an 11.53% CAGR According to strategic market researchNASDAQ OMX's News Release Distribution Channel, 2022GlobeNewswire, Inc.Digital Resources/Online E-Resources |
| 19 |
Material Type: Newsletter Article
|
|
Cancer Therapeutics Market Size to Surpass US$ 365.99 Bn by 2030: According to Precedence Research, the global cancer therapeutics market size is predicted to surpass US$ 365.99 billion by 2030 and expanding growth at a CAGR of 9.1% from 2022 to 2030NASDAQ OMX's News Release Distribution Channel, 2022GlobeNewswire, Inc.Digital Resources/Online E-Resources |
| 20 |
Material Type: Newsletter Article
|
|
Press Release: Poster on Celsion Corporation's Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's CancerDow Jones Institutional News, 2021Copyright Dow Jones & Company Inc Mar 2, 2021Digital Resources/Online E-Resources |
Results 1 - 20 of 2,379 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Personalize your results
Refine Search Results
Expand My Results
Show only
Refine My Results
Creation Date
- Before 2005 (6)
- 2005 To 2009 (15)
- 2010 To 2013 (2,288)
- 2014 To 2018 (38)
- After 2018 (33)
-
More options
New Records
Resource Type
- Newspaper Articles (2,264)
- Newsletter Articles (98)
- Articles (11)
- magazinearticle (3)
- Web Resources (2)
- Thesises (postgraduate) (1)
-
More options
Subject
- Womens Health (2,378)
- Breast Cancer (2,343)
- Pathology (2,260)
- Cancer Therapies (115)
- Oncology (63)
- Clinical Trials (59)
- Patients (58)
- Metastasis (53)
- Pharmaceutical Industry (48)
- Hospitals (41)
- Ovarian Cancer (40)
- Tumors (37)
- Alzheimer's Disease (31)
- Biotechnology Industry (30)
- Prostate Cancer (29)
- Fda Approval (28)
-
More options
Databases
- ProQuest Central (2,379)
- PubMed Central (6)
- ROAD: Directory of Open Access Scholarly Resources (6)
- DOAJ Directory of Open Access Journals (6)
- MEDLINE (4)
- Geneva Foundation Free Medical Journals at publisher websites (3)
- Springer Open Access (2)
- Taylor & Francis Open Access (1)
- Nature_OA刊 (1)
- ProQuest One Psychology (1)
- Dove Press Free (1)
-
More options
Journal Title
- Banbridge Leader (49)
- Chichester Observer (44)
- Crawley Observer (46)
- Dromore Leader (45)
- Lynn News (47)
- Newsletter (46)
- Rugby Advertiser (47)
- Skegness Standard (45)
- Stamford Mercury (47)
- Ulster Star (44)
-
More options
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||